Tuberculosis and Respiratory Diseases

  • 제56권5호
  • /
  • Pages.450-464
  • /
  • 2004
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

폐암 세포주에서 FHIT 유전자 이입에 의한 Apoptosis의 기전

Mechanism of FHIT-Induced Apoptosis in Lung Cancer Cell Lines

  • 유정선 (원자력병원 내과, 실험치료연구실) ;
  • 김철현 (원자력병원 내과, 실험치료연구실)
  • Yoo, Jung Sun (Department of Internal Medicine and Laboratory of Experimental Therapeutics, Korea Cancer Center Hospital) ;
  • Kim, Cheol Hyeon (Department of Internal Medicine and Laboratory of Experimental Therapeutics, Korea Cancer Center Hospital)
  • 발행 : 2004.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

연구배경 : FHIT 유전자의 homozygous deletion과 이와 관련된 mRNA 발현 이상, 단백질의 발현 결손은 폐암에서 매우 높은 빈도로 관찰되고 있다. 일부 연구에 의하면 FHIT 유전자를 폐암 세포 내에 이입시켰을 때 apoptosis가 유발되었고, 세포 주기의 이상 소견이 관찰되었으며, 종양형성 능력이 억제됨이 관찰되었다. 하지만 아직까지 FHIT 단백질의 기능에 대한 지식은 미진한 상태이다. 본 연구에서는 FHIT 유전자를 폐암 세포에 이입시켰을 때 유발되는 apoptosis의 기전을 규명하고자 하였다. 방 법 : FHIT 유전자가 결손된 NCI-H358 세포주에 FHIT 유전자를 stable transfection 시킨 후, cisplatin 혹은 paclitaxel을 가하고 apoptosis가 항진되어 나타나는가를 DAPI staining과 flow cytometry로 관찰해 보았다. 또한 이 과정에서 나타나는 caspase system의 변화와 Bcl-2 family의 변화를 Western blotting으로 조사해 보았다. 결 과 : FHIT를 발현시킨 세포에서는 cisplatin 혹은 paclitaxel을 투여하였을 때 유의하게 생존율이 감소하였으며, 이는 apoptosis 증가에 의한 것으로 확인 되었다. 이 과정에서 FHIT가 발현된 세포는 caspase-3, caspase-7의 활성화가 유의하게 증가되었으며, Bcl-2와 Bcl-xL 발현은 유의하게 감소하고 Bax와 Bad 발현은 유의하게 증가하였다. 결 론 : FHIT가 발현된 폐암 세포에 항암제를 투여하였을 때 유의하게 증가한 apoptosis는 caspase system과 Bcl-2 family의 활성화와 관련되어 있다.

Background : The FHIT (fragile histidine triad) gene is a frequent target of deletions associated with abnormal RNA and protein expression in lung cancer. Previous studies have shown FHIT gene transfer into lung cancer cell line lacking FHIT protein expression resulted in inhibition of tumor cell growth attributable to the induction of apoptosis and reversion of tumorigenecity. However, the mechanism of the tumor suppressor activity of the FHIT gene and the cellular pathways associated with its function are not completely understood. Methods : To gain insight into the biological function of FHIT, we compared the NCI-H358 cell line with its stable FHIT transfectants after treatment with cisplatin or paclitaxel. We investigated the effects of FHIT gene expression on cell proliferation, apoptosis, and activation of caspase system and Bcl-2 family. The induction of apoptosis was evaluated by using DAPI staining and flow cytometry. Activation of caspases and Bcl-2 members was evaluated by Western blot analysis. Results : A significantly increased cell death was observed in FHIT transfectants after cisplatin or paclitaxel treatment and this was attributable to the induction of apoptosis. Remarkable changes in caspases and Bcl-2 family were observed in the transfected cells as compared with the control cells after treatment with paclitaxel. Activation of caspase-3 and caspase-7 was markedly increased in cells expressing FHIT. Expression level of Bcl-2 and Bcl-xL protein was significantly decreased and that of Bax and Bad protein was significantly increased in the transfected cells. Conclusion : FHIT gene delivery into lung cancer cells results in enhanced apoptosis induced by treatment with cisplatin or paclitaxel. The data suggest that apoptosis in FHIT-expressing cells could be related to activation of caspase pathway and Bcl-2 family.

키워드

참고문헌

  1. Brauch H, Johnson B, Hovis J, Yano T,Gazdar A, Pettengill OS, Graziano S, Sore-nson GD, Poiesz BJ, Minna J, Linehan N, Zbar B. Molecular analysis of the short arm of chromosome 3 in small-cell and nonsmall-cell carcinoma of the lung. N Engl J Med 1987;317:1109-13
  2. Naylor SL, Johnson BE, Minna JD, Saka-guchi AY. Loss of heterozygosity of chro-mosome 3p markers in small-cell lung cancer. Nature(London) 1987;329:451-4
  3. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chro-mosome 3, 13, 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 1987;84:9252-6
  4. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 1992;7:445-9
  5. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Onco-gene 1992;7:1989-97
  6. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J Am Med Assoc 1995;273:558-63
  7. Killary AM, Wolf ME, Giambernardi TA, Naylor SL. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 1992;89:10877-81
  8. Daly MC, Xiang RH, Buchhagen D, Hensel CH, Garcia DK, Killary AM, Minna JD, Naylor SL. A homozygous deletion on chro-mosome 3 in a small cell lung cancer cell line correlates with a region of tumor sup-pressor activity. Oncogene 1993;8:1721-9
  9. Kok K, Hosfra R, Pilz A, van den Berg A, Terpstra P, Buys CH, Carrit B. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin activation enzyme. Proc Natl Acad Sci USA 1993;90:6071-5
  10. Sekido Y, Bader S, Latif F, Gnarra JR, Gadzar AF, Linehan M, Zbar B, Lerman MI, Minna JD. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 1994;9:1599-604
  11. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Heubner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associatedt(3;8)breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97
  12. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J, Huebner K. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996;56:978-83
  13. Sozzi G, Alder H, Tornielli S, Corletto V, Baffa R, Veronese ML, Negrini M, Pilotti S, Pierotti MA, Huebner K, Croce CM. Aber-rant FHIT transcripts in Merkel cell car-cinoma. Cancer Res 1996;56:2472-4
  14. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9
  15. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-5
  16. Smeets DF, Scheres JM, Hustinx TW. The most common fragile site in man is 3p14. Hum Genet 1986;72:215-20
  17. Huang Y, Garrison PN, Barnes LD. Cloning of the Schizosaccharomyces pombe gene encoding diadenosine $5'5'''-P^1,P^4$-tetrapho-sphate $(A_{P4}A)$ asymmetrical hydrolase: seque-nce similarity with histidine triad (HIT) family. Biochem J 1995;312:925-32
  18. Barnes LD, Garrison PN, Siprashvili Z, Gura-nowski A, Robinson AK, Ingram SW, Croce CM, Otha M, Huebner K. Fhit, a putative tumor suppressor in humans, is a dinu-cleoside 5', 5'''-P1,P3 triphosphate hydrolase. Biochemistry 1996;35:11529-35
  19. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, Gregorio LD, Pastorino U, Pierotti MA, Ohta M, Heubner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26
  20. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T, Taka-hashi T. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-82
  21. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial le-sions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-67
  22. Sozzi G, Tornielli S, Tagliabue E. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-12
  23. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM. The tumor-sup-pressor gene FHIT is involved in the regula-tion of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999;96:8489-92
  24. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhi-bition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histi-dine triad (FHIT) gene overexpression. Can-cer Res 1999;59:3333-9
  25. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cer-vical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-20
  26. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM. Effect of adenoviral transduction of the fragile histi-dine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84
  27. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36
  28. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapas-so F, Croce CM. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003;63:1183-7
  29. Askari MD, Vo-Dinh T. Implication of mito-chondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. Bio-polymers 2004;73:510-23